Just Healthcare

Just Healthcare

Share this post

Just Healthcare
Just Healthcare
Immunotherapy and TKIs Boost Survival in Older Adults With AL Leukemia

Immunotherapy and TKIs Boost Survival in Older Adults With AL Leukemia

New chemotherapy-free approaches may double long-term survival in older patients with acute lymphoblastic leukemia

Naveen Sankar S's avatar
Naveen Sankar S
Jun 13, 2025
∙ Paid
2

Share this post

Just Healthcare
Just Healthcare
Immunotherapy and TKIs Boost Survival in Older Adults With AL Leukemia
1
Share
Generated image

Topology

A shift from traditional chemotherapy to immunotherapy-based regimens, including blinatumomab, inotuzumab, and TKIs like ponatinib, is significantly improving outcomes in older adults with acute lymphoblastic leukemia (ALL), raising survival rates from under 20% to as high as 80%-90% in select groups.

Study Details

At the ASCO 2025 conference, Res…

Keep reading with a 7-day free trial

Subscribe to Just Healthcare to keep reading this post and get 7 days of free access to the full post archives.

Already a paid subscriber? Sign in
© 2025 Just Healthcare
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share